nature portfolio

Corresponding author(s):	Jemma Geoghegan; NCOMMS-24-43317
Last updated by author(s):	Jul 19, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

_				
C -	トつ	t١	ct	ics
	п		> 1	11 >

n/a	Confirmed
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection The GISAID RSV database was used to obtain global RSV genomes used in this analysis

Data analysis We us

We used open source software for this study: MAFFT (v 7), IQ-TREE (v 1.6.8), TempEst (v 1.5.3), Least Squares Dating, BEAST2 (v 2.6), R and Matlab.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our <u>policy</u>

The genomes generated are available on GISAID under two blocks of consecutive accession numbers (EPI_ISL_16959469 - EPI_ISL_16960152 and EPI_ISL_19206151 - EPI_ISL_19207488). We are in the process of uploading these genomes to NCBI.

Research involving human participants, their data, or biological material Policy information about studies with human participants or human data. See also policy information about sex, gender (identity/presentation),

•	out studies with <u>numan parti</u> and <u>race, ethnicity and raci</u>	ism.		
Reporting on sex an		ere generated from male and female sexes in equal proportions. We do not have data regarding gender and		
Reporting on race, e other socially releva groupings				
Population characteristics N/A				
Recruitment Samples we		btained from diagnostic laboratories associated with hospitals and primary healthcare facilities.		
Ethics oversight The New Zealand N		d Northern A Health and Disability Ethics Committee approved this study (NTX/11/11/102).		
Note that full informatio	n on the approval of the study p	protocol must also be provided in the manuscript.		
Field-spec	ific reporting	Σ Σ		
Please select the one	below that is the best fit for	your research. If you are not sure, read the appropriate sections before making your selection.		
X Life sciences	Behavioural & soc	cial sciences Ecological, evolutionary & environmental sciences		
For a reference copy of the	document with all sections, see <u>natu</u>	ure.com/documents/nr-reporting-summary-flat.pdf		
Life scienc	ces study des	ign		
All studies must disclo	ose on these points even who	en the disclosure is negative.		
Sample size In	total, 1,471 viral genomes, incl	tal, 1,471 viral genomes, including 756 RSV-A and 715 RSV-B sequences, were generated from New Zealand between 2015 and 2022.		
Data exclusions G	enomes comprising >50% ambi	es comprising >50% ambiguous sites were excluded.		
Replication	Analyses were performed multiple times, for example bootstrapping on phylogenetic trees.			
Randomization N	N/A			
Blinding N	N/A			
Reporting	for specific r	materials, systems and methods		
		of materials, experimental systems and methods used in many studies. Here, indicate whether each material, are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & expe	· · · · · · · · · · · · · · · · · · ·	Methods		
n/a Involved in the study		n/a Involved in the study		
Antibodies Eukaryotic cell lines		ChIP-seq Flow cytometry		
Palaeontology and archaeology		MRI-based neuroimaging		
	ther organisms			
Clinical data				
Dual use research	arch of concern			
Plants				

Plants

Seed stocks	N/A
Novel plant genotypes	N/A
Authentication	N/A